Ritu Baral
Stock Analyst at TD Cowen
(3.08)
# 1,502
Out of 5,182 analysts
45
Total ratings
41.46%
Success rate
4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HELP Cybin | Initiates: Buy | $8 | $5.40 | +48.15% | 1 | Apr 13, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Hold | $53 | $52.95 | +0.09% | 2 | Mar 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.30 | +65.92% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $272.75 | +12.19% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $29.40 | +127.89% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $135.98 | +77.23% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $128.64 | +3.39% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $1.86 | +330.11% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $330.99 | +6.65% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $37.28 | +95.82% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $390 → $554 | $520.09 | +6.52% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.67 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.80 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $308.51 | +20.26% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.12 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $20.98 | +734.13% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.18 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.78 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.60 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.34 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.21 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $402.59 | - | 2 | Jan 12, 2018 |
Cybin
Apr 13, 2026
Initiates: Buy
Price Target: $8
Current: $5.40
Upside: +48.15%
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Hold
Price Target: $53
Current: $52.95
Upside: +0.09%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.30
Upside: +65.92%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $272.75
Upside: +12.19%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $29.40
Upside: +127.89%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $135.98
Upside: +77.23%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $128.64
Upside: +3.39%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $1.86
Upside: +330.11%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $330.99
Upside: +6.65%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $37.28
Upside: +95.82%
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $520.09
Upside: +6.52%
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.67
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.80
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $308.51
Upside: +20.26%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.12
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $20.98
Upside: +734.13%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $57.18
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.78
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $19.60
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.34
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.21
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $402.59
Upside: -